Roche Licenses Rights to Develop Assay, Companion Dx for EGFR Mutations
November 23, 2010
Roche Licenses Rights to Develop Assay, Companion Dx for EGFR Mutations
In separate agreements, Roche has obtained a worldwide sub-license from Genzyme to develop the EGFR assay, and will collaborate with OSI Pharmaceuticals to develop the companion diagnostic.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Roche Gets Positive CHMP Review for Tarceva as First-line Treatment in EGFR-mutated NSCLC
July 27, 2011 / Pharmacogenomics Reporter - Qiagen Expands Companion Dx Portfolio with Three Licensing Deals; Exceeds 2012 QiaSymphony Placement Target
January 7, 2013 / GenomeWeb Daily News - MDx/CDx Focus: Enzo Launches Lung Cancer Dx; Zelboraf Survival Data; Caris' Tumor Profiling Service
November 14, 2012 / Pharmacogenomics Reporter - Ventana Sublicensing IP from Gen-Probe for ERG Protein Measurement
May 21, 2012 / GenomeWeb Daily News - Abbott, GSK Expand Partnership for Additional Companion Dx
November 28, 2011 / GenomeWeb Daily News